EMA accepts Clovis’ application for expanded indication of Rubraca to treat ovarian cancer

This article was originally published here

The European Medicines Agency (EMA) has accepted Clovis Oncology’s marketing application for a new indication of Rubraca (rucaparib) as maintenance treatment for women with recurrent ovarian cancer.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply